🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "major milestone" in the fight against increasingly resistant strains of the pathogen, according to scientists.

An International Public Health Issue

Cases of gonorrhoea are on the rise globally, with estimates suggesting in excess of 82 million new cases each year. Particularly high rates are reported in Africa and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely development in the face of growing infection rates, increasing antimicrobial resistance and the highly restricted available drugs at this time.”

Health officials are particularly alarmed about the surge in antibiotic-resistant strains. The global health body has designated it as a "critical concern". A tracking program showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Therapies Secure Clearance

Zoliflodacin, marketed under the name a brand name, was authorized by the US Food and Drug Administration in mid-December for use against gonorrhoea. This disease can lead to major issues, including the inability to conceive. Experts believe that focused deployment of this new drug will help slow the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GSK, gained clearance in close succession. This medication, which is employed against UTIs, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to bring it to fruition.

“This approval marks a huge turning point in the therapy of highly resistant gonorrhoea, which up to this point has been outpacing antibiotic development.”

Clinical Trial Data and Worldwide Availability

Based on results published in a major medical journal, zoliflodacin successfully treated the vast majority of uncomplicated infections. This places it at an equal footing with the existing first-line therapy, which involves an injection and a pill. The study enrolled nearly 1,000 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, the non-profit has the ability to register and commercialise the drug in numerous regions with limited resources.

Medical professionals on the front lines have voiced optimism. Access to a single-dose, oral treatment like this is described as a "revolutionary step" for managing the epidemic. This is considered crucial to reduce the burden of the illness for individuals and to halt the transmission of extremely resistant gonorrhoea around the world.